FDA Approves Takeda's Orzeyful (oveporexton) as First Full-Range Treatment for Narcolepsy Type 1
On September 9, 2026, the U.S. Food and Drug Administration (FDA) approved Takeda's Orzeyful (oveporexton), a twice-daily oral orexin receptor agonist, as the first drug cleared to treat the full range of symptoms of narcolepsy type 1 (NT1) in adults.
Clinical Significance and Paradigm Shift
Narcolepsy Type 1 is a chronic neurological disorder characterized by severe daytime sleepiness and cataplexy (sudden, temporary muscle weakness triggered by strong emotions). It is caused by a profound loss of orexin-producing neurons in the brain. Historically, treatments have focused on managing individual symptoms (e.g., stimulants for sleepiness, sodium oxybate or antidepressants for cataplexy).
Orzeyful acts directly on orexin receptors, addressing the underlying pathophysiology of the disease. It is the first and only oral therapy approved to treat the comprehensive spectrum of NT1 symptoms, representing a major therapeutic breakthrough.
Pivotal Trial Results
The approval was supported by robust clinical data from Phase 3 studies published in the New England Journal of Medicine (NEJM):
- Cataplexy Reduction: Treatment with Orzeyful resulted in a median reduction of up to 88.8% in sudden muscle-loss attacks (cataplexy).
- Wakefulness Improvement: Patients demonstrated highly statistically significant and clinically meaningful improvements in daytime wakefulness and overall quality of life.
- Safety: The drug showed a favorable safety profile, with no major unexpected toxicities reported during the Phase 3 trials.
"The FDA has approved Takeda's Orzeyful, a twice-daily pill and the first drug cleared to treat the full range of narcolepsy type 1 symptoms in adults... Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms." — Streamline Feed and Stocktitan Reports